整合酶抑制剂时代瑞士HIV队列潜在药物相互作用患病率
该研究通过链接利物浦HIV药物相互作用数据库与瑞士HIV队列研究数据,评估2018年接受治疗的HIV感染者中潜在药物相互作用(PDDIs)的患病率。共纳入9298人,29%存在至少一种PDDIs,其中2%为红色警示(主要与皮质类固醇相关),与2008年调查相同;含合并用药者中琥珀色和黄色警示PDDIs合计43%,低于2008年的59%。结论认为整合酶抑制剂的广泛使用降低了PDDIs患病率,但 boosted 方案的使用和老龄化人群合并用药增加阻碍了进一步下降。
要点
- 2018年瑞士HIV队列中29%的受治者存在至少一种潜在药物相互作用。
- 红色警示PDDIs占2%,主要涉及皮质类固醇,与2008年持平。
- 含合并用药者中琥珀色和黄色PDDIs合计43%,低于2008年的59%。
核心结论
- 2018年PDDIs患病率低于2008年,与整合酶抑制剂更广泛使用相关。
- boosted 方案持续使用和老龄化人群合并用药增加阻碍了PDDIs率进一步降低。
研究设计与样本
- 基于瑞士HIV队列研究(SHCS)2018年1–12月数据,链接利物浦HIV药物相互作用数据库评估PDDIs。
- 共纳入9298名接受治疗的HIV阳性个体,中位年龄51岁(IQR 43–58),72%为男性。
主要发现
- 68%的个体接受至少一种合并用药,14%存在多重用药(≥5种合并用药),29%存在至少一种PDDIs。
- 含合并用药者中,琥珀色和黄色PDDIs合计患病率为43%(琥珀色33%,主要与心血管药物相关;黄色20%),2008年为59%。
- 2%存在红色警示PDDIs(主要与皮质类固醇相关),与2008年调查相同。
- 与2008年相比,接受 boosted ARVs 者减少24%,NNRTIs减少13%,但合并用药使用更高。
关键数值与推荐
- PDDIs分类:红色警示为有害,琥珀色警示为潜在临床相关,黄色警示为弱临床意义。
- 方案分布:非增强整合酶抑制剂方案占40%, boosted ARVs 方案占30%,NNRTIs方案占32%。
临床怎么用
- 在整合酶抑制剂时代仍需系统筛查HIV感染者合并用药的潜在药物相互作用。
- 关注红色警示相互作用,尤其是与皮质类固醇相关的组合。
- 对使用 boosted 方案及多重用药的老年HIV感染者应加强药物相互作用管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prevalence of potential drug-drug interactions (PDDIs) between antiretroviral drugs (ARVs) and co-medications was high in 2008 in a Swiss HIV Cohort Study (SHCS) survey. We reassessed the prevalence of PDDIs in the era of human immunodeficiency virus (HIV) integrase inhibitors (INIs), characterized by more favorable interaction profiles. METHODS: The prevalence of PDDIs in treated HIV-positive individuals was assessed for the period 01-12/2018 by linkage of the Liverpool HIV drug interactions and SHCS databases. PDDIs were categorized as harmful (red flagged), of potential clinical relevance (amber flagged), or of weak clinical significance (yellow flagged). RESULTS: In 9298 included individuals, median age was 51 years (IQR, 43-58), and 72% were males. Individuals received unboosted INIs (40%), boosted ARVs (30%), and nonnucleoside reverse transcriptase inhibitor (NNRTIs) (32%)-based regimens. In the entire cohort, 68% received ≥1 co-medication, 14% had polypharmacy (≥5 co-medications) and 29% had ≥1 PDDI. Among individuals with co-medication, the prevalence of combined amber and yellow PDDIs was 43% (33% amber-mostly with cardiovascular drugs-and 20% yellow-flagged PDDIs) compared to 59% in 2008. Two percent had red-flagged PDDIs (mostly with corticosteroids), the same as in the 2008 survey. Compared with 2008, fewer individuals received boosted ARVs (-24%) and NNRTIs (-13%) but the use of co-medications was higher. CONCLUSIONS: Prevalence of PDDIs was lower with more widespread use of INIs in 2018 than in 2008. Continued use of boosted regimens and increasing needs for co-medications in this aging population impeded lower rates of PDDIs.
引用
- Deutschmann E, Bucher HC, Jaeckel S, et al. Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. Clin Infect Dis. 2021. PMID: 32634832. doi:10.1093/cid/ciaa918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。